SNN vs HOLX

For growth investors, Smith & Nephew plc (SNN) is the stronger pick with 6.

3% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Smith & Nephew plc (SNN) offers the better valuation at 21. 0x trailing P/E (13. 5x forward), making it the more compelling value choice. Analysts rate Smith & Nephew plc (SNN) a "Hold" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Smith & Nephew plc (SNN) is the cheapest at 21.

0x versus Hologic, Inc. at 30. 5x. On forward P/E, Smith & Nephew plc is actually cheaper at 13. 5x.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +16. 7%, compared to -21. 9% for Smith & Nephew plc (SNN). Over 10 years, the gap is even starker: HOLX returned +125. 4% versus SNN's +12. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus Smith & Nephew plc's 0. 59β — meaning SNN is approximately 45% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Hologic, Inc. (HOLX) carries a lower debt/equity ratio of 52% versus 63% for Smith & Nephew plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Smith & Nephew plc (SNN) is pulling ahead at 6.

3% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: Smith & Nephew plc grew EPS 53. 2% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, SNN leads at 5. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus 10. 1% for Smith & Nephew plc — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HOLX leads at 17. 4% versus 16. 3% for SNN. At the gross margin level — before operating expenses — SNN leads at 68. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Smith & Nephew plc (SNN) trades at 13.

5x forward P/E versus 17. 2x for Hologic, Inc. — 3. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SNN: 5. 8% to $32. 00.

In this comparison, SNN (2.

5% yield) pays a dividend. HOLX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Smith & Nephew plc (SNN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

59), 2. 5% yield). Both have compounded well over 10 years (SNN: +12. 4%, HOLX: +125. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

SNN pays a dividend while HOLX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.